Early assessment of endocan level as a predictor of remission status in acute leukemia patients
References
- Anitha GRJ, Chandraprabha VR, Padmakumar D, et al. (2024). Exploring the Prevalence and Prognostic Impact of Wilms Tumor 1 Exon 7 Mutation Status with Combinations of FLT3-ITD and NPM1 Mutations as Potential Molecular Biomarkers in Acute Myeloid Leukemia Patients with Normal Cytogenetics. Asian Pac J Cancer Prev, 25(10):3463–3470.
- De Angelis R, Minicozzi P, Sant M, et al. (2015). Survival variations by country and age for lymphoid and myeloid malignancies in europe 2000–2007: Results of eurocare-5 population-based study. Eur J Cancer, 51(15):2254–68.
- Terwilliger T., & Abdul-Hay, M. J. B. C. J. (2017). Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer Journal, 7:577.
- Paul S., Kantarjian H., & Jabbour E. J. (2016). Adult acute lymphoblastic leukemia. 91:1645–1666.
- Reikvam H, Hatfield KJ, Wendelbo Ø, et al. (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules, 12(4):492.
- Hatfield KJ, Lassalle P, Leiva RA, et al. (2011). Serum levels of endotheliumderived endocan are increased in patients with untreated acute myeloid leukemia. Hematology, 16(6):351–356.
- Huang X, Chen C, Wang X, et al. (2016). Prognostic value of endocan expression in cancers: evidence from meta-analysis. OncoTargets and Therapy, 9:6297–6304.
- Lin LY, Yeh YC, Chu CH, et al. (2017). Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors. Medicine, 96(41):8262.
- Yang YC, Pan KF, Lee WJ, et al. (2020). Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer. Cancer Res, 80:3292–3304.
- El Behery MM, Seksaka MA, Ibrahiem MA, et al. (2013). Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet, 288:1371–1376.
- Hendrix MJ, Seftor EA, Hess AR, et al. (2003). Molecular plasticity of human melanoma cells. Oncogene, 22:3070–3075.
- Arslan B, Onuk Ö, Hazar İ, et al. (2017). Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy. Tumori, 103(2):204–208.
- Steiner N, Hajek R, Sevcikova, et al. (2018). The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research, 38(9):5087–5092.
- Roccaro AM, Hideshima T, Raje N, et al. (2006). Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Res, 66(1):184–191.
Language: English
Submitted on: Aug 2, 2025
Accepted on: Nov 4, 2025
Published on: Mar 24, 2026
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2026 Rasha Magdy M Said, Tamer M. Ahmed, Rana Z. Abbas, Heba S. Agamy, Raed A. Shamkh, Basma S. M. Ali, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.